Ernexa Therapeutics (NASDAQ:ERNA) Coverage Initiated at Brookline Capital Markets

Equities research analysts at Brookline Capital Markets began coverage on shares of Ernexa Therapeutics (NASDAQ:ERNA) in a research note issued on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Brookline Capital Markets’ target price would suggest a potential upside of 298.41% from the stock’s previous close.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ernexa Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $30.00.

Ernexa Therapeutics Price Performance

ERNA opened at $7.53 on Thursday. The stock has a market capitalization of $8.81 million, a price-to-earnings ratio of -0.10 and a beta of 1.88. The business has a 50-day moving average of $5.89 and a two-hundred day moving average of $21.13. Ernexa Therapeutics has a 12 month low of $3.18 and a 12 month high of $100.46.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent SEC filing. 70.55% of the stock is owned by hedge funds and other institutional investors.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.